Should I buy or sell PepGen stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PepGen in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PEPG shares. View PEPG analyst ratings or view top-rated stocks .

What is PepGen's stock price target for 2024?

2 analysts have issued twelve-month target prices for PepGen's stock. Their PEPG share price targets range from $21.00 to $28.00. On average, they anticipate the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 70.5% from the stock's current price. View analysts price targets for PEPG or view top-rated stocks among Wall Street analysts .

How have PEPG shares performed in 2024?

PepGen's stock was trading at $6.80 at the beginning of the year. Since then, PEPG stock has increased by 115.6% and is now trading at $14.66. View the best growth stocks for 2024 here .

When is PepGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our PEPG earnings forecast .

What ETF holds PepGen's stock ?

Morningstar US Small Growth holds 3,223 shares of PEPG stock, representing 1.20% of its portfolio.

(PEPG) raised $126 million in an initial public offering on Friday, May 6th 2022. The company issued 9,000,000 shares at $13.00-$15.00 per share.

How do I buy shares of PepGen?

Shares of PEPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PEPG

PepGen (PEPG) Stock Price, News & Analysis

$14.66

-0.43 (-2.85%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $14.50
▼
$15.14
50-Day Range: $6.01
▼
$15.09
52-Week Range: $3.72
▼
$20.00

Volume: 54,800 shs
Average Volume: 156,500 shs
Market Capitalization: $349.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.00

Get PepGen alerts:

PepGen MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 70.5% Upside
$25.00 Price Target
Short Interest: Healthy
1.53% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.52
Based on 7 Articles This Week
Insider Trading: Acquiring Shares
$7,064 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.50) to ($3.66) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.53 out of 5 stars

Medical Sector

514th out of 922 stocks

Pharmaceutical Preparations Industry

239th out of 423 stocks

3.5

Analyst's Opinion

Consensus Rating
PepGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.00, PepGen has a forecasted upside of 70.5% from its current price of $14.66.
Amount of Analyst Coverage
PepGen has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.53% of the float of PepGen has been sold short.
Short Interest Ratio / Days to Cover
PepGen has a short interest ratio ("days to cover") of 4.4.
Change versus previous month
Short interest in PepGen has recently decreased by 3.92%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
PepGen does not currently pay a dividend.
Dividend Growth
PepGen does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PEPG.

2.5

News and Social Media Coverage

News Sentiment
PepGen has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for PepGen this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for PEPG on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
4 people have added PepGen to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PepGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,064.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 3.97% of the stock of PepGen is held by insiders.
Percentage Held by Institutions
71.80% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for PepGen are expected to decrease in the coming year, from ($3.50) to ($3.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PepGen is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PepGen is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
PepGen has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About PepGen Stock (NASDAQ:PEPG)

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD). The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is headquartered in Boston, Massachusetts.

PEPG Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PEPG Stock News Headlines

February 6, 2024 | marketbeat.com

PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data

PepGen stock is moving higher on expectations of positive Phase 2 clinical trial results for its Duchenne muscular dystrophy (DMD) gene therapy

February 8, 2024 | msn.com

PepGen Inc. Secures Funding to Advance Research Programs

February 12, 2024 | The Freeport Society (Ad)

Obama’s 2024 Confession

Barack Obama’s confession about the 2024 election just leaked online… In short, he’s worried Biden “could very well lose.” But before you think that means Trump will win… You should see the evidence I’ve found about an election shock that could come as soon as August 19th.

February 8, 2024 | msn.com

PepGen Inc. Announces Pricing for Its Offering

February 7, 2024 | tmcnet.com

PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock

February 7, 2024 | marketwatch.com

PepGen Stock Higher After Follow-on Offering

February 6, 2024 | msn.com

PepGen soars on Sarepta Therapeutics' Duchenne drug phase 2 data

February 2, 2024 | markets.businessinsider.com

Top 4 Health Care Stocks That May Crash This Quarter

February 12, 2024 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

January 31, 2024 | markets.businessinsider.com

Buy Rating Affirmed for PepGen Inc. on Strong Prospects in DMD Treatment and Promising EDO Platform

January 30, 2024 | msn.com

PepGen stock soars after rival Sarepta reports data for DMD drug

January 20, 2024 | seekingalpha.com

PepGen: Long Road Ahead

January 17, 2024 | finance.yahoo.com

Day One Announces Two New Appointments to Board of Directors

January 17, 2024 | finance.yahoo.com

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

January 12, 2024 | finance.yahoo.com

Institutions own 24% of PepGen Inc. (NASDAQ:PEPG) shares but private equity firms control 54% of the company

January 8, 2024 | finance.yahoo.com

PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

December 18, 2023 | finance.yahoo.com

PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

December 2, 2023 | finance.yahoo.com

We Think PepGen (NASDAQ:PEPG) Needs To Drive Business Growth Carefully

November 15, 2023 | finance.yahoo.com

PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors

November 11, 2023 | morningstar.com

PepGen Inc PEPG

November 10, 2023 | markets.businessinsider.com

Fein’s Buy Rating on Biogen: Leqembi’s Potential Growth and Market Penetration

November 8, 2023 | msn.com

PepGen GAAP EPS of -$0.98

November 8, 2023 | benzinga.com

PepGen: Q3 Earnings Insights

November 8, 2023 | finance.yahoo.com

PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

October 17, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Immuneering (IMRX), PepGen Inc. (PEPG)

October 13, 2023 | msn.com

FDA lifts clinical hold on PepGen’s myotonic dystrophy type 1 candidate

October 12, 2023 | markets.businessinsider.com

FDA Clearance and Pre-Clinical Success Bolster PepGen Inc.’s Buy Rating: An Analysis by Andrew Fein

See More Headlines

Receive PEPG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PepGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 2/11/2024
Next Earnings (Estimated): 3/28/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PEPG
CUSIP: N/A
CIK: 1835597
Web: www.pepgen.com
Phone: 781-797-0979
Fax: N/A
Employees: 63
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $25.00
High Stock Price Target: $28.00
Low Stock Price Target: $21.00
Potential Upside/Downside: +70.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-69,100,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -47.97%
Return on Assets: -38.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.35
Quick Ratio: 6.35

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.60 per share
Price / Book: 1.93

Miscellaneous

Outstanding Shares: 23,810,000
Free Float: 22,869,000
Market Cap: $349.05 million
Optionable: Not Optionable
Beta: 1.20

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. James G. McArthur Ph.D. (Age 62)
President, CEO, Treasurer, Secretary & Director
Comp: $834.98k
Mr. Noel P. Donnelly M.B.A. (Age 54)
Chief Financial Officer
Comp: $650.17k
Mr. Niels Svenstrup Ph.D. (Age 54)
Senior Vice President of Chemistry, Manufacturing & Control
Comp: $455.15k
Dr. Michael Gait Ph.D.
Founder & Scientific Advisory Board Member
Ms. Mary Beth DeLena
General Counsel & Secretary
Dr. Jaya Goyal Ph.D. (Age 56)
Executive Vice President of Research & Preclinical Development
Comp: $558.4k
Dr. Michelle L. Mellion M.D. (Age 48)
Senior VP & Head of Clinical Development
Mr. Kyle Breidenstine
VP of Finance & Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PEPG Stock Analysis - Frequently Asked Questions

Should I buy or sell PepGen stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PepGen in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PEPG shares.
View PEPG analyst ratings or view top-rated stocks.
What is PepGen's stock price target for 2024?: 2 analysts have issued twelve-month target prices for PepGen's stock. Their PEPG share price targets range from $21.00 to $28.00. On average, they anticipate the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 70.5% from the stock's current price.
View analysts price targets for PEPG or view top-rated stocks among Wall Street analysts.
How have PEPG shares performed in 2024?: PepGen's stock was trading at $6.80 at the beginning of the year. Since then, PEPG stock has increased by 115.6% and is now trading at $14.66.
View the best growth stocks for 2024 here.
When is PepGen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our PEPG earnings forecast.

What ETF holds PepGen's stock ?: Morningstar US Small Growth holds 3,223 shares of PEPG stock, representing 1.20% of its portfolio.
When did PepGen IPO?: (PEPG) raised $126 million in an initial public offering on Friday, May 6th 2022. The company issued 9,000,000 shares at $13.00-$15.00 per share.
How do I buy shares of PepGen?: Shares of PEPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PEPG) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial